CD4 and neoplasm: For MSLN-derived HLA class II-restricted peptides, we observed a significantly improved PFS and OS in patients with tumors presenting higher numbers of these peptides (p-value: 0.04 and 0.04, respectively, Figure 3C,D), highlighting the importance of MSLN-directed CD4+ immune responses for tumor immunosurveillance.